Pear Therapeutics (US)

Maria Sullivan


Dr. Sullivan serves as vice president, Clinical Development at Pear, leading the Translational, Clinical, and Clinical Operations teams. She previously served as the addiction franchise lead at Alkermes, where for 6 years she led a clinical research team conducting late-stage trials focused on initiation of opioid antagonist treatment and also served as executive medical director, Medical Affairs. Throughout her clinical research career, she has explored the efficacy of potential new therapeutics to improve care for patients suffering from addiction.

 Dr. Sullivan was an independent National Institute on Drug Abuse–funded principal investigator for 20 years at Columbia University and the New York State Psychiatric Institute, receiving continuous funding to carry out clinical studies focused on developing novel pharmacotherapies and behavioral treatments for opioid dependence and nicotine dependence. She was a member of the board of directors of the American Academy of Addiction Psychiatry and chair, Clinical Expert Committee, for the Substance Abuse and Mental Health–sponsored Prescribers’ Clinical Support System. Dr. Sullivan continues to serve on the voluntary faculty at Columbia University as associate professor of Clinical Psychiatry in the Division of Substance Use Disorders, Department of Psychiatry. She has also been a board-certified and practicing addiction psychiatrist for more than 20 years.

 Dr. Sullivan is the author of more than 100 peer-reviewed articles and book chapters and coeditor, Addiction in the Older Patient (Oxford University Press, 2016). She completed her education and training at Harvard, the University of Chicago, George Washington Medical School, and Columbia University.